{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:33:56Z","timestamp":1794285236624,"version":"4.9.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Human papillomavirus (HPV) is the most common sexually transmitted agent worldwide. Early prevention with HPV vaccination is a safe and effective method against this disease. HPV vaccines provided more protection against several oncogenic HPV strains. Three prophylactic HPV vaccines have been approved to target high-risk HPV types and protect against HPV-related disorders. These existing vaccines are based on the recombinant DNA technology and purified L1 protein that is assembled to form HPV empty shells. The prophylactic vaccines are highly immunogenic and can induce production of specific neutralizing antibodies. However, therapeutic vaccines are different from these prophylactic vaccines. They induced cell-mediated immunity against transformed cells, instead of neutralizing antibodies. The second generation of prophylactic HPV vaccines, made from alternative viral components using cost-effective production strategies, is undergoing clinical evaluation. The purpose of this review is to provide a complete and up-to-date review of the types of HPV vaccines and the efficiency of each of them for readers.<\/jats:p>","DOI":"10.3389\/fimmu.2021.805695","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T05:01:20Z","timestamp":1643259680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":129,"title":["An Update on Human Papilloma Virus Vaccines: History, Types, Protection, and Efficacy"],"prefix":"10.3389","volume":"12","author":[{"given":"Zahra","family":"Yousefi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Aria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhoodeh","family":"Ghaedrahmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Bastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2018.10.004","article-title":"Diagnosis of Transient\/Latent HPV Infections - A Point of View","volume":"49","author":"Perez-Campos Mayoral","year":"2018","journal-title":"Arch Med Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.08.005","article-title":"Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV","volume":"40","author":"Madrid-Marina","year":"2009","journal-title":"Arch Med Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2011.07.002","article-title":"HPV-16 and HLA-DRB1 Alleles Are Associated With Cervical Carcinoma in Mexican Mestizo Women","volume":"42","author":"Alaez-Verson","year":"2011","journal-title":"Arch Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.06.001","article-title":"HPV-Related Carcinogenesis: Basic Concepts, Viral Types and Variants","volume":"40","author":"Lizano","year":"2009","journal-title":"Arch Med Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bpobgyn.2017.08.015","article-title":"The Natural History of Human Papillomavirus Infection","volume":"47","author":"de Sanjose","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1984.tb01944.x","article-title":"A New Type of Papillomavirus DNA, its Presence in Genital Cancer Biopsies and in Cell Lines Derived From Cervical Cancer","volume":"3","author":"Boshart","year":"1984","journal-title":"EMBO J"},{"key":"B7","volume-title":"Human Papillomavirus Infections: Epidemiology and Disease Associations","author":"Palefsky","year":"2018"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic Classification of Human Papillomavirus Types Associated With Cervical Cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp020178","article-title":"Adding a Test for Human Papillomavirus DNA to Cervical-Cancer Screening","volume":"348","author":"Wright","year":"2003","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide Prevalence and Genotype Distribution of Cervical Human Papillomavirus DNA in Women With Normal Cytology: A Meta-Analysis","volume":"7","author":"De Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1086\/651620","article-title":"Sequential Acquisition of Human Papillomavirus (HPV) Infection of the Anus and Cervix: The Hawaii HPV Cohort Study","volume":"201","author":"Goodman","year":"2010","journal-title":"J Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000140012.02703.10","article-title":"Condom Use and Other Factors Affecting Penile Human Papillomavirus Detection in Men Attending a Sexually Transmitted Disease Clinic","volume":"31","author":"Baldwin","year":"2004","journal-title":"Sex Transm Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011688","article-title":"Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners","volume":"346","author":"Castellsagu\u00e9","year":"2002","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/infdis\/jiq021","article-title":"Age-Specific Prevalence of and Risk Factors for Anal Human Papillomavirus (HPV) Among Men Who Have Sex With Women and Men Who Have Sex With Men: The HPV in Men (HIM) Study","volume":"203","author":"Nyitray","year":"2011","journal-title":"J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/infdis\/jiq015","article-title":"External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents","volume":"203","author":"Vardas","year":"2011","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/infdis\/jiq016","article-title":"Prevalence of and Risk Factors for Human Papillomavirus (HPV) Infection Among HIV-Seronegative Men Who Have Sex With Men","volume":"203","author":"Goldstone","year":"2011","journal-title":"J Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1086\/507432","article-title":"Prevalence of HPV Infection Among Men: A Systematic Review of the Literature","volume":"194","author":"Dunne","year":"2006","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.4.244","article-title":"The Causal Relation Between Human Papillomavirus and Cervical Cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"key":"B19","article-title":"Review of HPV-Related Diseases and Cancers","volume":"40","author":"Brianti","year":"2017","journal-title":"New Microbiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.ygyno.2010.01.024","article-title":"Gynecologic Oncology Pathology and Epidemiology of HPV Infection in Females","volume":"117","author":"Stanley","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5315816","article-title":"Review Article New Insights in the Pathogenesis of HPV Infection and the Associated Carcinogenic Processes\u202f: The Role of Chronic Inflammation and Oxidative Stress","volume":"2018","author":"Georgescu","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160786","article-title":"The Human Papillomavirus Replication Cycle , and its Links to Cancer Progression\u202f: A Comprehensive Review","volume":"131","author":"Graham","year":"2017","journal-title":"Clin Sci"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-13-3438-2_9","article-title":"HPV Infection: Pathogenesis and Detection","volume-title":"Preventive Oncology for the Gynecologist","author":"Aggarwal","year":"2019"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1007\/s10156-012-0485-5","volume-title":"Immune Responses Against Human Papillomavirus (HPV) Infection and Evasion of Host Defense in Cervical Cancer","author":"Sasagawa","year":"2012"},{"key":"B25","volume-title":"Chapter 18. Immune Responses to Human Papillomavirus and the Development of Human Papillomavirus Vaccines","author":"Stanley","year":"2020"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2009.05.003","article-title":"Immunobiology of HPV Infection","volume":"40","author":"Garcia-Chacon","year":"2009","journal-title":"Arch Med Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bpobgyn.2017.08.001","article-title":"Host Control of Human Papillomavirus Infection and Disease","volume":"47","author":"Doorbar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bpobgyn.2017.08.001","article-title":"Host Control of Human Papillomavirus Infection and Disease","volume":"47","author":"Doorbar","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24447","article-title":"HPV Prevalence and Type-Distribution in Cervical Cancer and Premalignant Lesions of the Cervix: A Population-Based Study From Northern Ireland","volume":"88","author":"Anderson","year":"2016","journal-title":"J Med Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31027","article-title":"Immune Evasion Mechanisms of Human Papillomavirus: An Update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05028-11","article-title":"Epithelial Cell Responses to Infection With Human Papillomavirus","volume":"25","author":"Stanley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209950","article-title":"Viral Oncoproteins Target the DNA Methyltransferases","volume":"26","author":"Burgers","year":"2007","journal-title":"Oncogene"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/976024","article-title":"Pattern Recognition via the Toll-Like Receptor System in the Human Female Genital Tract","volume":"2010","author":"Nasu","year":"2010","journal-title":"Mediators Inflammation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.10.6764","article-title":"Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein Implication for the E7-Mediated Immune Evasion Mechanism in Cervical Carcinogenesis","volume":"275","author":"Park","year":"2000","journal-title":"J Biol Chem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab3291","article-title":"DNA Tumor Virus Oncogenes Antagonize the cGAS-STING DNA-Sensing Pathway","volume":"350","author":"Lau","year":"2015","journal-title":"Sci (80- )"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5420","article-title":"Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope From Human Papillomavirus 16 E6","volume":"167","author":"Evans","year":"2001","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044952","article-title":"Post-Transcriptional and Epigenetic Regulation of Antigen Processing Machinery (APM) Components and HLA-I in Cervical Cancers From Uighur Women","volume":"7","author":"Hasim","year":"2012","journal-title":"PloS One"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms13078338","article-title":"Role of Endoplasmic Reticulum Aminopeptidases in Health and Disease: From Infection to Cancer","volume":"13","author":"Cifaldi","year":"2012","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203860","article-title":"Transcriptional Regulation of the Major Histocompatibility Complex (MHC) Class I Heavy Chain, TAP1 and LMP2 Genes by the Human Papillomavirus (HPV) Type 6b, 16 and 18 E7 Oncoproteins","volume":"19","author":"Georgopoulos","year":"2000","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","first-page":"16086","DOI":"10.1038\/nrdp.2016.86","article-title":"Carcinogenic Human Papillomavirus Infection","volume":"2","author":"Schiffman","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.17179\/excli2018-1419","article-title":"Association Between miR-124-1 Rs531564 Polymorphism and Risk of Cancer: An Updated Meta-Analysis of Case-Control Studies","volume":"17","author":"Moazeni-Roodi","year":"2018","journal-title":"EXCLI J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12325-015-0178-4","article-title":"Early Direct and Indirect Impact of Quadrivalent HPV (4hpv) Vaccine on Genital Warts: A Systematic Review","volume":"32","author":"Mariani","year":"2015","journal-title":"Adv Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human Papillomavirus Vaccines \u2013 Immune Responses","volume":"30","author":"Stanley","year":"2012","journal-title":"Vaccine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00188","article-title":"The Use of Both Therapeutic and Prophylactic Vaccines in the Therapy of Papillomavirus Disease","volume":"11","author":"Garbuglia","year":"2020","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11356-021-15441-w","article-title":"Physiopathology and Effectiveness of Therapeutic Vaccines Against Human Papillomavirus","volume":"28","author":"Ayesha","year":"2021","journal-title":"Environ Sci Pollut Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0234","article-title":"Local HPV Recombinant Vaccinia Boost Following Priming With an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-Cell\u2013Mediated Tumor Control in the Genital Tract","volume":"22","author":"Sun","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, Efficacy, and Immunogenicity of VGX-3100, a Therapeutic Synthetic DNA Vaccine Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins for Cervical Intraepithelial Neoplasia 2\/3: A Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6317","article-title":"Clearance of Persistent HPV Infection and Cervical Lesion by Therapeutic DNA Vaccine in CIN3 Patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16\u2013Related Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"Oct 7","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic Vaccines for HPV-Associated Malignancies","volume":"9","author":"Smalley Rumfield","year":"2020","journal-title":"ImmunoTargets Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.113","article-title":"Progress in Prophylactic Human Papillomavirus (HPV) Vaccination in 2016: A Literature Review","volume":"36","author":"Maver","year":"2018","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/ijgc-2019-000582","article-title":"Human Papillomavirus (HPV) Vaccination: From Clinical Studies to Immunization Programs","volume":"29","author":"Murillo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV Vaccines\u2013a Review of the First Decade","volume":"146","author":"Harper","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22527","article-title":"Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Lesions: A Meta-Analysis Update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1586\/erv.09.123","article-title":"Currently Approved Prophylactic HPV Vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.03.016","article-title":"Gardasil-9: A Global Survey of Projected Efficacy","volume":"130","author":"Zhai","year":"2016","journal-title":"Antiviral Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.069","article-title":"Human Papillomavirus Vaccines: WHO Position Paper, May 2017\u2013Recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial","volume":"309","author":"Dobson","year":"2013","journal-title":"Jama"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-Dose Schedule for Human Papillomavirus Vaccination\u2014Updated Recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"key":"B61","first-page":"1","article-title":"Human Papillomavirus Vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"Morb Mortal Wkly Rep Recomm Rep"},{"key":"B62","first-page":"300","article-title":"Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0625-z","article-title":"Safety of Human Papillomavirus Vaccines: An Updated Review","volume":"41","author":"Phillips","year":"2018","journal-title":"Drug Saf"},{"key":"B64","doi-asserted-by":"publisher","first-page":"100185","DOI":"10.1016\/j.pvr.2019.100185","article-title":"Infection and Vaccine-Induced HPV-Specific Antibodies in Cervicovaginal Secretions . A Review of the Literature","volume":"8","author":"Pattyn","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469","article-title":"High Sustained Efficacy of a Prophylactic Quadrivalent Human Papillomavirus Types 6\/11\/16\/18 L1 Virus-Like Particle Vaccine Through 5 Years of Follow-Up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained Efficacy and Immunogenicity of the Human Papillomavirus (HPV)-16\/18 AS04-Adjuvanted Vaccine: Analysis of a Randomised Placebo-Controlled Trial Up to 6.4 Years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet (London England)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000773","article-title":"A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil\u00ae in 9\u201315-Year-Old Girls","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents: A Randomized Controlled Trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.08.059","article-title":"Safety and Immunogenicity of a 9-Valent HPV Vaccine in Females 12\u201326 Years of Age Who Previously Received the Quadrivalent HPV Vaccine","volume":"33","author":"Garland","year":"2015","journal-title":"Vaccine"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of Early Adolescent Females With Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Heal"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1155","article-title":"Ten-Year Immune Persistence and Safety of the HPV-16\/18 AS 04-Adjuvanted Vaccine in Females Vaccinated at 15\u201355 Years of Age","volume":"6","author":"Schwarz","year":"2017","journal-title":"Cancer Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic Responses Following Administration of a Vaccine Targeting Human Papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1","article-title":"Cross-Protective Efficacy of Two Human Papillomavirus Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Malag\u00f3n","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71179-9","article-title":"Next Generation Prophylactic Human Papillomavirus Vaccines","volume":"16","author":"Schiller","year":"2015","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/01443615.2018.1493441","article-title":"New Prophylactics Human Papilloma Virus (HPV) Vaccines Against Cervical Cancer","volume":"39","author":"Barra","year":"2019","journal-title":"J Obstet Gynaecol (Lahore)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02478","article-title":"Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus","volume":"9","author":"Dadar","year":"2018","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2016.11.020","article-title":"Developments in L2-Based Human Papillomavirus (HPV) Vaccines","volume":"231","author":"Schellenbacher","year":"2017","journal-title":"Virus Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines","volume":"83","author":"Schellenbacher","year":"2009","journal-title":"J Virol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3390\/vaccines8040568","article-title":"Progress in L2-Based Prophylactic Vaccine Development for Protection Against Diverse Human Papillomavirus Genotypes and Associated Diseases","volume":"8","author":"Olczak","year":"2020","journal-title":"Vaccines"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2017.03.004","article-title":"Characterization of a Spray-Dried Candidate HPV L2-VLP Vaccine Stored for Multiple Years at Room Temperature","volume":"3","author":"Peabody","year":"2017","journal-title":"Papillomavirus Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00874","article-title":"Cutaneous Papillomaviruses and non-Melanoma Skin Cancer: Causal Agents or Innocent Bystanders","volume":"9","author":"Hasche","year":"2018","journal-title":"Front Microbiol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00146-7","article-title":"Phase I Safety and Antigenicity of TA-GW: A Recombinant HPV6 L2E7 Vaccine for the Treatment of Genital Warts","volume":"17","author":"Thompson","year":"1999","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1086\/314616","article-title":"Phase IIa Safety and Immunogenicity of a Therapeutic Vaccine, TA-GW, in Persons With Genital Warts","volume":"179","author":"Lacey","year":"1999","journal-title":"J Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1548282","article-title":"Efficacy and Safety of Prophylactic HPV Vaccines. A Cochrane Review of Randomized Trials","volume":"17","author":"Arbyn","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.028","article-title":"Seropositivity to non-Vaccine Incorporated Genotypes Induced by the Bivalent and Quadrivalent HPV Vaccines: A Systematic Review and Meta-Analysis","volume":"35","author":"Bissett","year":"2017","journal-title":"Vaccine"},{"key":"B87","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.vaccine.2017.11.034","article-title":"Comparative Immunogenicity and Safety of Human Papillomavirus (HPV)-16\/18 AS04-Adjuvanted Vaccine and 4vhpv Vaccine Administered According to Two-or Three-Dose Schedules in Girls Aged 9\u201314 Years: Results to Month 36 From a Randomized Trial","volume":"36","author":"Leung","year":"2018","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw865","article-title":"Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study","volume":"64","author":"Toh","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.017","article-title":"Antibody Persistence and Evidence of Immune Memory at 5 Years Following Administration of the 9-Valent HPV Vaccine","volume":"35","author":"Guevara","year":"2017","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.22034\/APJCP.2018.19.8.2313","article-title":"Immune Response to Human Papillomavirus One Year After Prophylactic Vaccination With AS04-Adjuvanted HPV-16\/18 Vaccine: HPV-Specific IgG and IgA Antibodies in the Circulation and the Cervix","volume":"19","author":"Costa","year":"2018","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1159\/000497617","article-title":"HPV Vaccine: Updates and Highlights","volume":"63","author":"de Oliveira","year":"2019","journal-title":"Acta Cytol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12913-016-1824-5","article-title":"Experiences and Lessons Learned From 29 HPV Vaccination Programs Implemented in 19 Low and Middle-Income Countries, 2009-2014","volume":"16","author":"Ladner","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.pvr.2019.04.004","article-title":"Impact of HPV Vaccination: Achievements and Future Challenges","volume":"7","author":"Brotherton","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1086\/529207","article-title":"Acquisition of Anal Human Papillomavirus (HPV) Infection in Women: The Hawaii HPV Cohort Study","volume":"197","author":"Goodman","year":"2008","journal-title":"J Infect Dis"},{"key":"B95","article-title":"Knockdown of SLC39A7 Suppresses Cell Proliferation, Migration and Invasion in Cervical Cancer","volume":"16","author":"Wei","year":"2017","journal-title":"EXCLI J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.805695\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T05:01:31Z","timestamp":1643259691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.805695\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2021.805695"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.805695","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"article-number":"805695"}}